ArticleNature reviews. Gastroenterology & hepatology2017
NASH: Novel therapeutic strategies targeting ASK1 in NASH.
Article in Nature reviews. Gastroenterology & hepatology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed.
- MASLD: Spatial Mechanisms and New Therapeutics.Biomolecules · 2026Review
- Design, synthesis, and biological evaluation of FXR/ASK1 dual-target modulators.Beilstein journal of organic chemistry · 2026Article
- The emerging role of E3 ubiquitin ligases and deubiquitinases in metabolic dysfunction-associated steatotic liver disease.Journal of translational medicine · 2025Review
- The role of ubiquitination and deubiquitination in the pathogenesis of non-alcoholic fatty liver disease.Frontiers in immunology · 2025Review
- Synthesis and biological evaluation of quinoxaline derivatives as ASK1 inhibitors.Journal of enzyme inhibition and medicinal chemistry · 2024Article
- Potential therapeutic strategies for MASH: from preclinical to clinical development.Life metabolism · 2024Review
- Active role of the immune system in metabolic dysfunction-associated steatotic liver disease.Gastroenterology report · 2024Review
- Hyperphosphorylation of hepatic proteome characterizes nonalcoholic fatty liver disease in S-adenosylmethionine deficiency.iScience · 2023Article
- Recent Advances in PROTACs for Drug Targeted Protein Research.International journal of molecular sciences · 2022Review
- Mitochondria homeostasis: Biology and involvement in hepatic steatosis to NASH.Acta pharmacologica Sinica · 2022Article
- Roles of hepatic stellate cells in NAFLD: From the perspective of inflammation and fibrosis.Frontiers in pharmacology · 2022Review
- Nonalcoholic Steatohepatitis Promoting Kinases.Seminars in liver disease · 2020Review
- Endoplasmic reticulum stress and autophagy dysregulation in alcoholic and non-alcoholic liver diseases.Clinical and molecular hepatology · 2020Review
- Interleukin-22 Ameliorates Neutrophil-Driven Nonalcoholic Steatohepatitis Through Multiple Targets.Hepatology (Baltimore, Md.) · 2020Article
- Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone?International journal of molecular sciences · 2020Review
- Targeting the Inositol Pyrophosphate Biosynthetic Enzymes in Metabolic Diseases.Molecules (Basel, Switzerland) · 2020Review
- Systematic Identification of Regulators of Oxidative Stress Reveals Non-canonical Roles for Peroxisomal Import and the Pentose Phosphate Pathway.Cell reports · 2020Article
- ASK1 inhibition reduces cell death and hepatic fibrosis in an Nlrp3 mutant liver injury model.JCI insight · 2020Article
- Current and Emerging Approaches for Nonalcoholic Steatohepatitis Treatment.Gene expression · 2019Review
- Innate immune regulatory networks in hepatic lipid metabolism.Journal of molecular medicine (Berlin, Germany) · 2019Review
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
28377639What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.